{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T15:40:11Z","timestamp":1781710811432,"version":"3.54.5"},"reference-count":25,"publisher":"MDPI AG","issue":"24","license":[{"start":{"date-parts":[[2024,12,11]],"date-time":"2024-12-11T00:00:00Z","timestamp":1733875200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Ministry of Health, Italy"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background\/Objectives: In the era of biotechnological drugs, methotrexate (MTX) still represents the first-line treatment in chronic inflammatory arthritis, such as rheumatoid arthritis (RA), psoriatic arthritis (PsA), and undifferentiated arthritis (UA). The aim of our study was to evaluate the persistence of MTX as a first-line treatment in a group of patients with chronic inflammatory arthritis. Methods: We conducted a retrospective analysis of a database of outpatients diagnosed with RA, PsA, or UA who visited our Rheumatology Clinic from January 2014 to January 2022. Key demographic and clinical data, including information on comorbidities and treatments, were routinely collected. Kaplan\u2013Meier (KM) curves were used to determine the persistence of MTX during follow-up. Results: A total of 242 patients with chronic inflammatory arthritis who initiated MTX as first-line therapy and had available clinical data were included. Of these, 130 (53.7%) had RA, 82 (33%) had PsA, and 30 (16.3%) had UA. Overall, the survival rate of MTX at 24 months of follow-up was approximately 60%, while at 48 months and 96 months, it was 40% and 20%, respectively. A statistically significant difference was found between RA and PsA compared to UA (Chi-square test = 14.84; p = 0.001). When comparing the KM survival curves of MTX between male and female patients, obese and non-obese individuals, as well as older (age \u2265 50 years) and younger patients (age &lt; 50 years), no statistically significant differences were observed in any of the comparisons. Conclusions: Our study confirmed the efficacy and overall safety of MTX in RA and PsA, with good persistence even over the long term.<\/jats:p>","DOI":"10.3390\/jcm13247540","type":"journal-article","created":{"date-parts":[[2024,12,11]],"date-time":"2024-12-11T12:38:56Z","timestamp":1733920736000},"page":"7540","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Long-Term Survival of Methotrexate as First-Line Therapy in Rheumatoid Arthritis, Psoriatic Arthritis and Undifferentiated Arthritis"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3771-5205","authenticated-orcid":false,"given":"Fabio Massimo","family":"Perrotta","sequence":"first","affiliation":[{"name":"Academic Rheumatology Unit, Department of Medicine and Health Sciences \u201cVincenzo Tiberio\u201d, University of Molise, 86100 Campobasso, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9398-0428","authenticated-orcid":false,"given":"Pasquale","family":"Ambrosino","sequence":"additional","affiliation":[{"name":"Istituti Clinici Scientifici Maugeri IRCCS, Scientific Directorate of Telese Terme Institute, 82037 Telese Terme, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6189-5328","authenticated-orcid":false,"given":"Ennio","family":"Lubrano","sequence":"additional","affiliation":[{"name":"Academic Rheumatology Unit, Department of Medicine and Health Sciences \u201cVincenzo Tiberio\u201d, University of Molise, 86100 Campobasso, Italy"},{"name":"Istituti Clinici Scientifici Maugeri IRCCS, Cardiac Rehabilitation Unit of Telese Terme Institute, 82037 Telese Terme, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,12,11]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1136\/ard-2024-225531","article-title":"EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update","volume":"83","author":"Gossec","year":"2024","journal-title":"Ann. Rheum. Dis."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/s41584-022-00798-0","article-title":"Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): Updated treatment recommendations for psoriatic arthritis 2021","volume":"18","author":"Coates","year":"2022","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1177\/1759720X16654476","article-title":"Remission-induction therapies for early rheumatoid arthritis: Evidence to date and clinical implications","volume":"8","author":"Espinoza","year":"2016","journal-title":"Ther. Adv. Musculoskelet. Dis."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1002\/art.40851","article-title":"Etanercept and Methotrexate as Monotherapy or in Combination for Psoriatic Arthritis: Primary Results From a Randomized, Controlled Phase III Trial","volume":"71","author":"Mease","year":"2019","journal-title":"Arthritis Rheumatol."},{"key":"ref_5","first-page":"S51","article-title":"An overview of low disease activity and remission in psoriatic arthritis","volume":"33","author":"Lubrano","year":"2015","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1136\/ard.60.8.729","article-title":"Anti-inflammatory mechanisms of methotrexate in rheumatoid arthritis","volume":"60","author":"Cutolo","year":"2001","journal-title":"Ann. Rheum. Dis."},{"key":"ref_7","first-page":"760","article-title":"Acontrolledtwo- centre trial of parenteral methotrexate therapy for refractory rheumatoid arthritis","volume":"11","author":"Thompson","year":"1984","journal-title":"J. Rheumatol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"489","DOI":"10.7326\/0003-4819-103-4-489","article-title":"Weekly pulse methotrexate in rheumatoid arthritis","volume":"103","author":"Andersen","year":"1985","journal-title":"Ann. Intern. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1056\/NEJM198503283121303","article-title":"EYcacy of low-dose methotrexate in rheumatoid arthritis","volume":"312","author":"Weinblatt","year":"1985","journal-title":"N. Engl. J. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1093\/rheumatology\/kes001","article-title":"A randomized placebo-controlled trial of methotrexate in psoriatic arthritis","volume":"51","author":"Kingsley","year":"2012","journal-title":"Rheumatology"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1136\/ard.2009.113308","article-title":"Effec-tiveness and retention rates of methotrexate in psoriatic arthritis in comparison with meth-otrexate-treated patients with rheumatoid arthritis","volume":"69","author":"Lie","year":"2010","journal-title":"Ann. Rheum. Dis."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1007\/s00296-023-05305-6","article-title":"Long-term persistence of oral methotrexate and associated factors in rheumatoid arthritis: A retrospective cohort study","volume":"43","author":"Dhir","year":"2023","journal-title":"Rheumatol. Int."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/BF00290296","article-title":"Long-term experience with low dose methotrexate in rheu-matoid arthritis","volume":"13","author":"Tishler","year":"1993","journal-title":"Rheumatol. Int."},{"key":"ref_14","first-page":"1139","article-title":"Factors influencing length of time taking methotrexate in rheumatoid arthritis","volume":"27","author":"Ortendahl","year":"2000","journal-title":"J. Rheumatol."},{"key":"ref_15","first-page":"261","article-title":"Disease modifying antirheumatic drugs in early rheumatoid arthritis: A longterm observa-tional study","volume":"29","author":"Papadopoulos","year":"2002","journal-title":"J. Rheumatol."},{"key":"ref_16","first-page":"2325","article-title":"Longterm observational study of methotrexate use in a Dutch cohort of 1022 patients with rheumatoid arthritis","volume":"30","author":"Hoekstra","year":"2003","journal-title":"J. Rheumatol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1136\/ard.2004.023408","article-title":"Long term safety of methotrexate in routine clinical care: Discontinuation is unusual and rarely the result of laboratory abnormalities","volume":"64","author":"Yazici","year":"2005","journal-title":"Ann. Rheum. Dis."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1097\/01.rhu.0000260526.29331.a8","article-title":"Risk factors associated with the cumulative survival of low-dose methotrexate in 273 Japanese patients with rheumatoid arthritis","volume":"13","author":"Ideguchi","year":"2007","journal-title":"J. Clin. Rheumatol."},{"key":"ref_19","first-page":"181","article-title":"Therapeutic maintenance dose with methotrexate in rheumatoid polyarthritis. Prospective study of 191 cases","volume":"59","author":"Anaya","year":"1992","journal-title":"Rev. Rhum. Mal. Osteoartic"},{"key":"ref_20","first-page":"125","article-title":"Long-term survival of methotrexate in psoriatic arthritis","volume":"61","author":"Ricci","year":"2009","journal-title":"Reumatismo"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"vi5","DOI":"10.1093\/rheumatology\/kes279","article-title":"ACR\/EULAR 2010 rheumatoid arthritis classification criteria","volume":"51","author":"Kay","year":"2012","journal-title":"Rheumatology"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.1002\/art.21972","article-title":"Classification criteria for psoriatic arthritis: Development of new criteria from a large international study","volume":"54","author":"Taylor","year":"2006","journal-title":"Arthritis Rheum."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/S0140-6736(07)61602-X","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: Guidelines for reporting observational studies","volume":"370","author":"Altman","year":"2007","journal-title":"Lancet"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1093\/rheumatology\/35.5.453","article-title":"Effect of age on the efficacy and tolerance of meth-otrexate in rheumatoid arthritis","volume":"35","author":"Bologna","year":"1996","journal-title":"Br. J. Rheumatol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"826","DOI":"10.3899\/jrheum.190299","article-title":"Comparative Persistence of Methotrexate and Tumor Necrosis Factor Inhibitors in Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis","volume":"47","author":"George","year":"2019","journal-title":"J. Rheumatol."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/13\/24\/7540\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:52:22Z","timestamp":1760115142000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/13\/24\/7540"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,11]]},"references-count":25,"journal-issue":{"issue":"24","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["jcm13247540"],"URL":"https:\/\/doi.org\/10.3390\/jcm13247540","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,11]]}}}